O4I2
目录号 : GC17042
An inducer of Oct3/4
Cas No.:165682-93-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Target: Oct3; Oct4
IC50: N/A
O4I2, a potent Oct3/4 inducer, is suitable for iPSC generation [1]. The octamer-binding transcription factor 4 (Oct3/4), a member of the POU family of transcription factors, is expressed specifically in pluripotent cells such as induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs). Oct3/4 plays a critical role in regulation of the cellular pluripotency core network. The loss-of-function mutation or suppression of Oct3/4 in embryonic stem cells (ESCs) leads to differentiation of ESCs into trophoblast and loss of pluripotency, whereas gain-of-function or forced overexpression Oct3/4, can reprogram somatic cells back into pluripotent stem cells (iPSCs) [1].
In vitro: O4I2 (5, 10, and 20 μM) dose-dependently activated Oct3/4 expression in HEK293 cells, embryonal NCCIT cells, and also in Oct-deficient HeLa cells [1]. In addition, O4I2 (10, and 20 μM) activated Oct3/4 on the transcriptional and translational level in human neonatal foreskin fibroblasts (HFFs), and promoted pluripotency-associated genes (Nanog and Lin28) expression [1].
In vivo: N/A
Reference:
1. Cheng X, Yoshida H, Raoofi D, Saleh S, Alborzinia H, Wenke F, et al. Ethyl 2-((4-Chlorophenyl)amino)thiazole-4-carboxylate and Derivatives Are Potent Inducers of Oct3/4. J Med Chem. 2015;58(15):5742-50.
| Cas No. | 165682-93-9 | SDF | |
| 化学名 | ethyl 2-((4-chlorophenyl)amino)thiazole-4-carboxylate | ||
| Canonical SMILES | CCOC(C1=CSC(NC2=CC=C(Cl)C=C2)=N1)=O | ||
| 分子式 | C12H11ClN2O2S | 分子量 | 282.75 |
| 溶解度 | ≥ 28.3mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5367 mL | 17.6835 mL | 35.3669 mL |
| 5 mM | 0.7073 mL | 3.5367 mL | 7.0734 mL |
| 10 mM | 0.3537 mL | 1.7683 mL | 3.5367 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。